A detailed history of Morgan Stanley transactions in Pure Tech Health PLC stock. As of the latest transaction made, Morgan Stanley holds 100 shares of PRTC stock, worth $2,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 2,827 96.46%
Holding current value
$2,029
Previous $70,000 97.14%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.42 - $25.0 $52,958 - $68,175
-2,727 Reduced 96.46%
100 $2,000
Q2 2024

Aug 14, 2024

BUY
$23.78 - $32.98 $67,226 - $93,234
2,827 New
2,827 $70,000

Others Institutions Holding PRTC

About PureTech Health plc


  • Ticker PRTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,888,500
  • Market Cap $566M
  • Description
  • PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholi...
More about PRTC
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.